Stage IVA pulmonary squamous cell carcinoma with nasal and bone metastases: response after paclitaxel, carboplatin, and tislelizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 15%

Metastatic Site: nasal region/skin; bone (left acromion)

The lung tumor and nasal metastasis regressed after paclitaxel/carboplatin plus tislelizumab, symptoms improved, no immune-related pneumonitis/colitis/hepatitis occurred, and progression-free survival exceeded 12 months.

PubMed CentralRead more →

ALK-Positive Metastatic Lung Cancer Responding to Lorlatinib During Hemodialysis

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: ALK rearrangement 80%; EGFR and BRAF negative; ROS1 negative; PD-L1 negative

Metastatic Site: brain

After about 1 year of lorlatinib, imaging was almost compatible with a complete response, brain MRI showed no active lesions, and she continued treatment with manageable high cholesterol as the main reported side effect.

PubMed CentralRead more →

Lung Adenocarcinoma That Transformed to Small Cell Cancer After Recurrence

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 1%-24%; no druggable driver alteration identified

Metastatic Site: brain, liver

After treatment for the small-cell-transformed recurrence, the liver metastases showed sustained regression and progression-free survival had reached 13 months by September 2024.

PubMed CentralRead more →

MET Y1003N-Mutant Lung Adenocarcinoma Responding to Tepotinib

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: MET mutation

Metastatic Site: bone

Tepotinib produced an 8-month response after many earlier treatments, but the cancer later recurred and she died about 3 years after treatment began.

PubMed CentralRead more →

EGFR-Mutant Lung Cancer With Pleomorphic Transformation Treated With Local Surgery

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR L858R mutation; PD-L1 less than 1% initially and greater than 75% after transformation

Metastatic Site: brain

Nine months after surgery for isolated progression, no recurrence had been seen and she remained on osimertinib.

PubMed CentralRead more →

Stage 4 lung cancer: complete response to chemoimmunotherapy and surgery

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR exon 20 duplication with PD-L1 TPS 70%; P40/CK5/6 positive squamous markers; Ki-67 60%.

Metastatic Site: right adrenal gland; possible adjacent…

As of May 7, 2024, CT follow-up showed no evidence of disease after chemoimmunotherapy, conversion surgery with pathologic complete response, and pembrolizumab maintenance.

PubMed CentralRead more →

Stage IV ALK Lung Adenocarcinoma: Shirley's Patient Story

Patient Info: Shirley, Female, Under 40 | Stage IV

Biomarkers: ALK mutation

As of December 2024, Shirley was living with Stage IV ALK-positive lung adenocarcinoma and had stable disease on a fourth-generation ALK inhibitor clinical trial that began in July 2024.

The Patient StoryRead more →

How Clinical Trials Helped Me Fight Stage 4 Cancer

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ALK-positive / ALK-rearranged

Metastatic Site: Not specified

As of December 2024, this anonymized patient described living 10.5 years with Stage IV non-small cell lung cancer and said her current clinical-trial treatment was working, with tumors shrinking.

The Patient StoryRead more →

Stage IV lung cancer: brain metastasis complete response after chemoimmunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS-mutated; BRG-1 partial loss; PD-L1 TPS 5%; CPS 20

Metastatic Site: brain (right cerebellar hemisphere)

The right cerebellar brain metastasis completely resolved and chest CT showed only postsurgical changes after carrelizumab plus paclitaxel/carboplatin; immune-mediated adrenal insufficiency improved with systemic glucocorticoids.

PubMed CentralRead more →

Doctors Assured Me It Wasn’t Cancer!

Patient Info: Shirley, Female, Under 40 | Stage IV

Biomarkers: ALK-rearranged

Metastatic Site: mediastinum, pleura

Shirley was living with Stage IV ALK-positive lung cancer on a phase 2 ALK clinical trial; scans remained stable after 2 scan sets, but the large mass persisted.

The Patient StoryRead more →

Small Cell Lung Cancer With Paraneoplastic Cushing Syndrome Treated With Immunochemotherapy

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 negative; low tumor mutation burden; microsatellite stable

Metastatic Site: liver, abdominal wall, left ilium

He lived 20 months after diagnosis. After repeated treatment responses and later progression, he died in September 2023 from respiratory and cardiac failure during a severe infection following treatment-related myelosuppression.

PubMed CentralRead more →

Stage IV lung adenocarcinoma: ROS1 fusion detected after immunotherapy resistance and partial response to entrectinib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial lung adenocarcinoma markers supported lung origin; PD-L1 <1%, no target found at first. Later testing found CD74-ROS1 fusion.

Metastatic Site: brain, bilateral lung lesions

As of December 2024, repeat imaging after entrectinib showed partial response in lung disease and regression of brain metastases, with the patient stable and willing to continue treatment.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Leah's Patient Story

Patient Info: Leah Phillips, Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Not reported

As of December 2024, Leah was recovering well a few weeks after right-middle-lobe lobectomy, but remained a Stage IV EGFR-mutated lung cancer patient needing ongoing treatment and follow-up.

MD AndersonRead more →

Stage IV ROS1 Non-Small Cell Lung Cancer: Ashley's Survivor Story

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: ROS1-rearranged

Metastatic Site: spine/bone

As of December 2024, Ashley described herself as having no evidence of active disease while continuing nightly ROS1-targeted therapy.

The Patient StoryRead more →

Stage IV lung adenocarcinoma: clinical complete remission with pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: No EGFR/ALK/BRAF driver alteration; PD-L1 <1%; high TMB in tissue and blood; immune-cell markers reported.

Metastatic Site: bilateral lungs, mediastinal lymph nodes, right hilar…

Clinical complete remission by RECIST while receiving pembrolizumab monotherapy for driver-negative, PD-L1-negative, high-TMB Stage IV lung adenocarcinoma.

PubMed CentralRead more →

Stage IV Lung Cancer: Natalie's Patient Story

Patient Info: Natalie, Female | Stage IV

Metastatic Site: lungs, lymph nodes

As of December 2024, Natalie had restarted chemotherapy after progression, and the current chemotherapy had stopped growth for the moment while she continued transplant evaluation.

The Patient StoryRead more →

Metastatic EGFR-positive lung adenocarcinoma: osimertinib cardiomyopathy managed with SGLT2 inhibitor support

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-positive; specific EGFR sequence variant not reported in extracted case text

As of December 2024, he remained clinically stable and asymptomatic 12 months after osimertinib rechallenge with empagliflozin, losartan, metoprolol, and close cardiac monitoring; the extracted case focuses on cardiotoxicity management rather than tumor response.

PubMed CentralRead more →

Stage IV Lung Adenocarcinoma With Delayed Pembrolizumab-Related Pneumonitis

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: contralateral lung

After brachytherapy and continued pembrolizumab, imaging 1 year later showed a smaller right hilar lesion with otherwise stable disease. She later recovered from delayed pembrolizumab-related pneumonitis after immunotherapy had been stopped.

PubMed CentralRead more →

Stage IV ALK Lung Cancer: Amanda's Patient Story

Patient Info: Amanda, Female, Under 40 | Stage IV

Biomarkers: ALK-rearranged

Metastatic Site: pleural fluid, right clavicle lymph node

As of December 2024, Amanda had lived with Stage IV ALK-positive lung cancer for about 2 years and was taking 8 targeted-therapy pills daily.

The Patient StoryRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Filipe's Patient Story

Patient Info: Filipe, Male, Under 40 | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain, bone, left lung, kidney

As of November 2024, Filipe was living with ongoing Stage IV EGFR exon 19-mutated lung cancer after initial response to osimertinib, later progression and current amivantamab plus chemotherapy.

The Patient StoryRead more →

Lung Adenocarcinoma With Immune-Related Abdominal Inflammation and Later Bone Progression

Patient Info: Anonymized, male | Stage IV

Biomarkers: PD-L1 30%; KRAS G13X mutation; EGFR/ALK/ROS1 negative

Metastatic Site: bone

After several periods of response or stability, lymph-node progression recurred and bone progression was documented in July 2024. Another treatment line was being planned.

PubMed CentralRead more →

Stage 4 ALK-positive lung cancer: remission on lorlatinib

Patient Info: Anonymized, Male, Under 40 | Stage IV

Biomarkers: ALK-positive rearrangement; TTF-1-positive

Metastatic Site: bilateral lungs, mediastinal lymph nodes, bone, liver,…

Metastatic ALK-positive lung adenocarcinoma remained in radiologic and clinical remission on lorlatinib after CNS progression on earlier ALK-directed therapy and stereotactic radiosurgery.

PubMed CentralRead more →

Stage IV HER2-Positive Non-Small Cell Lung Cancer: Samantha's Patient Story

Patient Info: Samantha, Female | Stage IV

Biomarkers: HER2 mutation

Metastatic Site: Lungs/pleural fluid; liver

As of November 2024, Samantha reported a 55% reduction across the board on chemotherapy plus immunotherapy, few side effects, improved energy, and enough function to hike, work, and feel more like herself.

The Patient StoryRead more →

Stage 4 small-cell lung cancer: ongoing response to immunotherapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1-negative

Metastatic Site: liver, bone, brain

Extensive-stage small-cell lung cancer had complete response in the primary lung, liver, bone, and treated brain lesions, with partial response in hilar/mediastinal nodes; after about 20 months of serplulimab-based first-line therapy, the patient had no deterioration, no immunotherapy-related adverse effects, and high quality of life.

PubMed CentralRead more →